Leukemia Therapy Shows Potent Activity Against Rare Ovarian Cancer, Study Finds

Leukemia Therapy Shows Potent Activity Against Rare Ovarian Cancer, Study Finds
Ponatinib, an approved leukemia therapy sold under the brand name Iclusig, may be effective against tumors in a rare and aggressive form of ovarian cancer, research suggests. Led by researchers at the Translational Genomics Research Institute (TGen), the study, “Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *